A task force, composed of key antitrust enforcement agencies including the Federal Trade Commission (FTC), and the Canadian Competition Bureau, is seeking information from the public regarding the effects of pharmaceutical mergers. This information will be used to update the practices for future pharmaceutical mergers by the task force’s constituent agencies. 

Following concerns within the agencies that their current practice of reviewing pharmaceutical mergers ignores the competitive landscape in the sector, the new information collected from the public will better address all anticompetitive effects from pharmaceutical mergers and acquisitions. The task force will use these new ideas to understand when concerns are likely to arise and when to challenge and oppose problematic mergers. 

For further information, please see this recent client alert by Reed Smith partners Ross Mackenzie, Michelle A. Mantine, and Isabelle Rahman